[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100560442":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":21,"centralContacts":27,"locations":33,"responsibleParty":50,"collaborators":21,"id":52,"slug":21,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":21,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":21,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":71,"overallStatus":36,"whyStopped":21,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental group","EXPERIMENTAL","Experimental arm",[13,14],"Drug: Sintilimab + IL-2 Combined with CAPOX","Radiation: Short-course radiotherapy",[16,22],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Sintilimab + IL-2 Combined with CAPOX","Sintilimab + IL-2 Combined with Capox",[9],null,{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":21},"RADIATION","Short-course radiotherapy","Short-course radiotherapy+IL-2",[9],[28],{"name":29,"role":30,"phone":31,"phoneExt":21,"email":32},"Yueming Sun","CONTACT","025-68306026","jssym@vip.sina.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Jiangsu Province Hospital","RECRUITING","Nanjing","Jiangsu","210000","China","CN",{"type":43,"coordinates":44},"Point",[45,46],118.77778,32.06167,{"lat":46,"lon":45},[49],{"name":29,"role":30,"phone":31,"phoneExt":21,"email":21},{"type":51,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100560442",false,"NCT06577194","Neoadjuvant Short-Course Radiotherapy Followed by CAPOX Plus PD-1 Antibody and IL-2 in Locally Advanced Rectal Cancer","A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n* Males and females aged between 18 and 70 years;\n* ECOG (Eastern Cooperative Oncology Group) performance status score of 0 or 1;\n* Tumor tissue samples obtained and histologically confirmed as rectal adenocarcinoma;\n* Adequate hematological, liver, and kidney functions: neutrophil count ≥ 1.5×10\\^9\u002FL; platelet count ≥ 75×10\\^9\u002FL; serum total bilirubin ≤ 1.5× upper limit of normal (UNL); aspartate aminotransferase ≤ 2.5× UNL; alanine aminotransferase ≤ 2.5× UNL; serum creatinine ≤ 1.5× UNL.\n\nExclusion Criteria:\n\n* Metastatic disease (Stage IV);\n* Recurrent rectal cancer;\n* Concurrent active bleeding, perforation, or other complex situations that cannot be addressed with emergency colostomy surgery alone;\n* Previous systemic anti-cancer treatment for colorectal cancer;\n* Coexistence of other non-colorectal cancer malignancies;\n* Patients with any active autoimmune diseases, or a history of needing steroids or immunosuppressive drugs;\n* Patients with interstitial lung disease, non-infectious pneumonia, or uncontrolled systemic diseases (e.g., diabetes, hypertension, pulmonary fibrosis, and acute pneumonia);\n* Previous treatment-induced any grade 2 or above toxicity reaction (according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5 classification) that has not subsided (excluding anemia, hair loss, and skin pigmentation);\n* Previous treatment with anti-programmed death receptor-1 (PD-1) or its ligand (PD-L1) antibodies, anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies;\n* Pregnant or breastfeeding women;\n* Known or tested positive for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS);\n* Known or suspected allergy history to any drugs used in the trial.","ALL","18 Years","70 Years",{"count":62,"type":63},35,"ESTIMATED","INTERVENTIONAL",[66],"PHASE2","A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer",[69,70],"Rectal Cancer","Advanced Solid Tumor",[72,24,73],"Immunotherapy","IL-2","2026-06-22",{"date":76,"type":77},"2026-06-24","ACTUAL",{"date":79,"type":77},"2024-10-05",{"date":81,"type":63},"2028-10-31",{"name":5,"class":6},1]